SOURCE-LINKED INTELLIGENCE

Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours

CORDIS · observation · Publication date unknown

Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours This proposal aims to validate artificial intelligence (AI)-designed minibinders and blockers of the growth factor Midkine (MDK) as anticancer agents to bypass resistance to current immunotherapies. The rationale stems from reports by our laboratory in Nature, Nature Medicine, EMBO Mol Reports and Nature Cancer describing pro-metastatic and immunosuppressive functions of MDK in melanoma, the most aggressive form of skin cancer. In particular, our work identified MDK as a driver of the “hot-into-cold” switch that underlies immune evasion and resistance to immune checkpoint blockade. We have also described immunomodulatory roles of MDK in gliomas, lung adenocarcinomas and kidney renal carcinomas, among others. These data are backed by an increasing number of independent studies reporting a broad

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

150000

unit

EUR